Literature DB >> 23027854

Is warfarin the right anticoagulant in idiopathic pulmonary fibrosis?

Elisabeth Bendstrup, Ole Hilberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23027854      PMCID： PMC3480518          DOI： 10.1164/ajrccm.186.7.693

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  9 in total

1.  Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung.

Authors:  A Fryer; Y C Huang; G Rao; D Jacoby; E Mancilla; R Whorton; C A Piantadosi; T Kennedy; J Hoidal
Journal:  J Pharmacol Exp Ther       Date:  1997-07       Impact factor: 4.030

2.  Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation.

Authors:  James H Finigan; Steven M Dudek; Patrick A Singleton; Eddie T Chiang; Jeffrey R Jacobson; Sara M Camp; Shiu Q Ye; Joe G N Garcia
Journal:  J Biol Chem       Date:  2005-02-14       Impact factor: 5.157

3.  Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents.

Authors:  A Koenig; K Norgard-Sumnicht; R Linhardt; A Varki
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

Review 4.  Structural determinants of antiproliferative activity of heparin on pulmonary artery smooth muscle cells.

Authors:  H G Garg; B T Thompson; C A Hales
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2000-11       Impact factor: 5.464

5.  Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease.

Authors:  A Günther; P Mosavi; C Ruppert; S Heinemann; B Temmesfeld; H G Velcovsky; H Morr; F Grimminger; D Walmrath; W Seeger
Journal:  Thromb Haemost       Date:  2000-06       Impact factor: 5.249

6.  Anticoagulant therapy for idiopathic pulmonary fibrosis.

Authors:  Hiroshi Kubo; Katsutoshi Nakayama; Masaru Yanai; Tomoko Suzuki; Mutsuo Yamaya; Mika Watanabe; Hidetada Sasaki
Journal:  Chest       Date:  2005-09       Impact factor: 9.410

7.  Role of protease-activated receptor-2 in idiopathic pulmonary fibrosis.

Authors:  Malgorzata Wygrecka; Grazyna Kwapiszewska; Ewa Jablonska; Susanne von Gerlach; Ingrid Henneke; Dariusz Zakrzewicz; Andreas Guenther; Klaus T Preissner; Philipp Markart
Journal:  Am J Respir Crit Care Med       Date:  2011-03-11       Impact factor: 21.405

8.  Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury.

Authors:  Chris J Scotton; Malvina A Krupiczojc; Melanie Königshoff; Paul F Mercer; Y C Gary Lee; Naftali Kaminski; John Morser; Joseph M Post; Toby M Maher; Andrew G Nicholson; James D Moffatt; Geoffrey J Laurent; Claudia K Derian; Oliver Eickelberg; Rachel C Chambers
Journal:  J Clin Invest       Date:  2009-08-03       Impact factor: 14.808

9.  A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.

Authors:  Imre Noth; Kevin J Anstrom; Sara Bristol Calvert; Joao de Andrade; Kevin R Flaherty; Craig Glazer; Robert J Kaner; Mitchell A Olman
Journal:  Am J Respir Crit Care Med       Date:  2012-05-03       Impact factor: 21.405
  9 in total
  2 in total

1.  Uncoupling of the profibrotic and hemostatic effects of thrombin in lung fibrosis.

Authors:  Barry S Shea; Clemens K Probst; Patricia L Brazee; Nicholas J Rotile; Francesco Blasi; Paul H Weinreb; Katharine E Black; David E Sosnovik; Elizabeth M Van Cott; Shelia M Violette; Peter Caravan; Andrew M Tager
Journal:  JCI Insight       Date:  2017-05-04

Review 2.  Idiopathic pulmonary fibrosis: early detection and referral.

Authors:  Justin M Oldham; Imre Noth
Journal:  Respir Med       Date:  2014-04-04       Impact factor: 3.415
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.